Dr. Donoghue is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3101 Ellicott St Nw
Washington, DC 20008Phone+1 202-487-9658Fax+1 202-476-5685
Education & Training
- Children's National Hospital/George Washington UniversityFellowship, Pediatric Hematology/Oncology, 2006 - 2009
- MedStar Health/Georgetown University HospitalResidency, Pediatrics, 1995 - 1998
- Emory University School of MedicineClass of 1995
Certifications & Licensure
- DC State Medical License 1998 - 2024
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 201 citationsFDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid TumorsLeigh Marcus, Lola Fashoyin-Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodriguez
Clinical Cancer Research. 2021-06-03 - 38 citationsFDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.Abhilasha Nair, Kelie Reece, Martha Donoghue, Weishi Vivian Yuan, Lisa Rodriguez
The Oncologist. 2021-03-01 - 30 citationsFDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.Erica C Nakajima, Paz J. Vellanki, Erin Larkins, Somak Chatterjee, Pallavi S. Mishra-Kalyani
Clinical Cancer Research. 2021-08-30
Press Mentions
- ODAC Meets to Assess FDA Reauthorization Act ChangesJune 5th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: